<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01785316</url>
  </required_header>
  <id_info>
    <org_study_id>SUGBG-013001</org_study_id>
    <nct_id>NCT01785316</nct_id>
  </id_info>
  <brief_title>The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases</brief_title>
  <acronym>SCANDIUM</acronym>
  <official_title>The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Linkoeping</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uppsala University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Skane University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Umeå</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized controlled, open-label, multi-centre study evaluating if Isolated Hepatic&#xD;
      Perfusion (IHP) increases Overall Survival compared with Best Alternative Care (BAC) in&#xD;
      patients with isolated liver metastases from uveal melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Uveal melanoma is the most common primary intraocular malignancy in adults. Despite&#xD;
      successful control of the primary tumor, metastatic disease will ultimately develop in&#xD;
      approximately 50% of the patients. The liver is the most common site for metastases, and&#xD;
      about 50% of the patients will have isolated liver metastases. These metastases are generally&#xD;
      refractory to systemic chemotherapy and the median survival for patients with liver&#xD;
      metastases is about 6 months. Regardless of treatment, the mortality rate is approximately&#xD;
      90% at 2 years with only about 1% of the patients surviving more than 5 years.&#xD;
&#xD;
      Isolated hepatic perfusion (IHP) is a regional treatment that was first performed more than&#xD;
      40 years ago (Aust and Ausman 1960). During IHP, the liver is completely isolated from the&#xD;
      systemic circulation, allowing a high concentration of chemotherapy to be perfused through&#xD;
      the liver with minimal systemic exposure. In a previous study from our institution, IHP was&#xD;
      analysed based on improvements in the procedure and the results showed an improved outcome&#xD;
      together with minimized morbidity and mortality over time.&#xD;
&#xD;
      A phase II follow-up study confirms that IHP is a promising technique with tolerable&#xD;
      morbidity. There are yet no randomized trials comparing overall survival in IHP, but in an&#xD;
      attempt to answer this question the investigators did a register study showing a 14 months&#xD;
      increased survival when comparing the patients treated with IHP with the longest surviving&#xD;
      patients in Sweden during the same time period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 15, 2013</start_date>
  <completion_date type="Anticipated">March 15, 2023</completion_date>
  <primary_completion_date type="Actual">March 15, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
    <description>OS defined as the frequency of individuals alive at 24 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hepatic progression-free survival</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as time from randomization to progress of existing lesions, or appearance of new lesions, within the liver according to RECIST criteria (version 1.1) using CT or MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as best response according to RECIST criteria (version 1.1) using CT or MRI. For the BAC-group, during the whole follow-up of 24 months. For the IHP-group, until hepatic progression (the time point when cross-over to the BAC-group is allowed).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economic evaluation</measure>
    <time_frame>24 months</time_frame>
    <description>Health economic evaluation measured using QALY calculated using EQ5D-3L at all study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAE</measure>
    <time_frame>24 months</time_frame>
    <description>Number of Participants with SAE as a Measure of Safety</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Melanoma</condition>
  <condition>Uveal Neoplasms</condition>
  <arm_group>
    <arm_group_label>IHP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isolated Hepatic Perfusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAC</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Best alternative care</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IHP</intervention_name>
    <arm_group_label>IHP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female aged above 18 years.&#xD;
&#xD;
          2. Signed and dated written informed consent before the start of specific protocol&#xD;
             procedures.&#xD;
&#xD;
          3. Histologically or cytologically proven liver metastases of uveal melanoma. If this is&#xD;
             not possible at the time of randomization, a biopsy is mandatory before start of&#xD;
             treatment.&#xD;
&#xD;
          4. Liver metastases measurable by MRI (preferred) or CT of thorax and abdomen according&#xD;
             to RECIST version 1.1 with at least one unidimensional measurable lesion ≥ 10 mm. The&#xD;
             examination should be within 4 weeks prior to randomization.&#xD;
&#xD;
          5. ECOG performance status of 0 or 1.&#xD;
&#xD;
          6. No previous chemotherapy, radiotherapy, or biologic therapy for uveal melanoma&#xD;
             metastases (ie first-line therapy)&#xD;
&#xD;
          7. Adequate hepatic function (defined as ASAT,ALAT, bilirubin &lt;= 3*ULN and PK-INR &lt;= 1.5)&#xD;
             and no medical history of liver cirrhosis or portal hypertension&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. More than 50% of the liver volume (measured by CT or MRI) replaced by tumour.&#xD;
&#xD;
          2. Evidence of extrahepatic disease by PET-CT&#xD;
&#xD;
          3. Life expectancy of less than 4 months&#xD;
&#xD;
          4. Pregnant or breast-feeding. Women of childbearing potential must have a negative&#xD;
             pregnancy test performed within seven days prior to the start of study.&#xD;
&#xD;
          5. Active infection.&#xD;
&#xD;
          6. Ischemic cardiac disease or history of congestive heart failure with an LVEF &lt; 40%.&#xD;
&#xD;
          7. COPD or other chronic pulmonary disease with PFT's indicating an FEV&lt; 50% predicted&#xD;
             for age.&#xD;
&#xD;
          8. Reduced renal function defined as S-Creatinine &gt;=1.5xULN or Creatinine Clearance &lt; 40&#xD;
             mL/min, calculated using the Cockroft and Gault formula.&#xD;
&#xD;
          9. Reduced blood leukocytes or platelets defined as LPK &lt; 2.0x109/L and TPK &lt;100x109/L&#xD;
&#xD;
         10. Use of live vaccines four weeks before or after the start of study.&#xD;
&#xD;
         11. Body mass index above 35.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger Olofsson Bagge, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://www.scandiumtrial.se</url>
    <description>Scandium Trial webpage</description>
  </link>
  <reference>
    <citation>Rizell M, Mattson J, Cahlin C, Hafström L, Lindner P, Olausson M. Isolated hepatic perfusion for liver metastases of malignant melanoma. Melanoma Res. 2008 Apr;18(2):120-6. doi: 10.1097/CMR.0b013e3282f8e3c9.</citation>
    <PMID>18337648</PMID>
  </reference>
  <reference>
    <citation>Olofsson R, Cahlin C, All-Ericsson C, Hashimi F, Mattsson J, Rizell M, Lindnér P. Isolated hepatic perfusion for ocular melanoma metastasis: registry data suggests a survival benefit. Ann Surg Oncol. 2014 Feb;21(2):466-72. doi: 10.1245/s10434-013-3304-z. Epub 2013 Oct 19.</citation>
    <PMID>24141377</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 1, 2013</study_first_submitted>
  <study_first_submitted_qc>February 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2013</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Roger Olofsson Bagge, MD, PhD</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Perfusion Cancer Chemotherapy, Regional</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

